Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Advances in Cancer Research
|
June 28, 2011
Proteolytic control of the oncoprotein transcription factor Myc
Lance R Thomas, William P Tansey
The Journal of Biological Chemistry
|
July 11, 2002
Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen
Lance R Thomas, David J Stillman, Andrew Thorburn
Advances in Experimental Medicine and Biology
|
September 8, 2009
Dynamic regulation of antigen receptor gene assembly
Lance R Thomas, Robin Milley Cobb, Eugene M Oltz
Biotechniques
|
March 3, 2004
pRS yeast vectors with a LYS2 marker
Peter Eriksson, Lance R Thomas, Andrew Thorburn, et al.
The Journal of Biological Chemistry
|
September 29, 2004
The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation
Lance R Thomas, Ronald L Johnson, John C Reed, et al.
Nature Immunology
|
October 24, 2006
Control of thymocyte development and recombination-activating gene expression by the zinc finger protein Zfp608
Feng Zhang, Lance R Thomas, Eugene M Oltz, et al.
Cancer Research
|
September 19, 2015
The MYC-WDR5 Nexus and Cancer
Lance R Thomas, Audra M Foshage, April M Weissmiller, et al.
The Journal of Biological Chemistry
|
June 3, 2004
Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD
Lance R Thomas, Adrianna Henson, John C Reed, et al.
The Journal of Biological Chemistry
|
August 2, 2007
Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding
Lianghua Bin, Jacqueline Thorburn, Lance R Thomas, et al.
Molecular & Cellular Oncology
|
March 12, 2020
Targeting MYC through WDR5
Lance R Thomas, Clare M Adams, Stephen W Fesik, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Advances in Cancer Research
|
June 28, 2011
Proteolytic control of the oncoprotein transcription factor Myc
Lance R Thomas, William P Tansey
The Journal of Biological Chemistry
|
July 11, 2002
Regulation of Fas-associated death domain interactions by the death effector domain identified by a modified reverse two-hybrid screen
Lance R Thomas, David J Stillman, Andrew Thorburn
Advances in Experimental Medicine and Biology
|
September 8, 2009
Dynamic regulation of antigen receptor gene assembly
Lance R Thomas, Robin Milley Cobb, Eugene M Oltz
Biotechniques
|
March 3, 2004
pRS yeast vectors with a LYS2 marker
Peter Eriksson, Lance R Thomas, Andrew Thorburn, et al.
The Journal of Biological Chemistry
|
September 29, 2004
The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation
Lance R Thomas, Ronald L Johnson, John C Reed, et al.
Nature Immunology
|
October 24, 2006
Control of thymocyte development and recombination-activating gene expression by the zinc finger protein Zfp608
Feng Zhang, Lance R Thomas, Eugene M Oltz, et al.
Cancer Research
|
September 19, 2015
The MYC-WDR5 Nexus and Cancer
Lance R Thomas, Audra M Foshage, April M Weissmiller, et al.
The Journal of Biological Chemistry
|
June 3, 2004
Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD
Lance R Thomas, Adrianna Henson, John C Reed, et al.
The Journal of Biological Chemistry
|
August 2, 2007
Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding
Lianghua Bin, Jacqueline Thorburn, Lance R Thomas, et al.
Molecular & Cellular Oncology
|
March 12, 2020
Targeting MYC through WDR5
Lance R Thomas, Clare M Adams, Stephen W Fesik, et al.
Page
of 3